Novartis Partners with SHYFT to Support its Digital Transformation
July 24 2018 - 4:00AM
Business Wire
Agreement accelerates Novartis’ ability to use
data and digital to transform commercial models, ensuring more
meaningful interactions with healthcare providers
SHYFT Analytics, a Medidata Solutions (NASDAQ:MDSO) company,
announced today that Novartis has selected its Intelligent Platform
for Life Sciences to support the commercialization of key therapies
in Europe.
Novartis will use the following SHYFT solutions:
- STRATA Data Platform to aggregate and
manage a growing number of third party and proprietary commercial
data sources
- LUMEN Insights Platform to deliver
intuitively-designed analytics to drive the “next-best-actions” for
commercial teams
Together, these solutions simplify and accelerate the
aggregation, assimilation, and analysis of scores of disparate data
sets that inform commercial sales and medical education
programs.
“Pharma companies are acutely aware of the tremendous demands on
healthcare professionals’ time. Every minute is important, and
every interaction we have with a healthcare professional must be
efficient, relevant, and impactful,” said Bertrand Bodson, Chief
Digital Officer at Novartis. “Medidata and SHYFT have come together
in a way that allows us to share data and insights seamlessly
across our Clinical Development and Commercial teams. We are
committed to reimagining medicine with data and digital, and this
technology helps us do that by supporting our Pharma sales reps
with intelligence-driven ‘next-best-actions’ so they can make the
100,000 interactions they have with HCPs every day as personalized
and meaningful as possible.”
Novartis’ new partnership with SHYFT extends its existing
collaboration with Medidata in support of its clinical trials and
commercialization programs. Medidata and SHYFT provide the
Intelligent Platform for Life Sciences, an end-to-end data and
analytics solution that empowers life sciences organizations to
close the loop between clinical and commercial insights and
accelerate their digital transformation.
“Novartis is leading the charge on accelerating value and
optimizing outcomes in life sciences because they approach
innovation with the care, forethought, and agility typically found
in much smaller organizations,” said Zack King, EVP Medidata and
President of SHYFT. “We are thrilled about our role in Novartis’
path toward digital transformation and are honored to partner with
them as they take on some of the biggest global challenges in
healthcare.”
About SHYFT
SHYFT Analytics, a Medidata company, is the leading platform for
commercial and real-world data analytics with products designed
specifically for the pharmaceutical, biotech, and medical device
industry. SHYFT’s data analytics platform is the most efficient and
scalable way to transform massive amounts of complex healthcare
data into on-demand clinical and commercial insight. SHYFT is
headquartered in Boston with offices in San Francisco and New York
City. Learn more about SHYFT at www.shyftanalytics.com, or follow
the company on Twitter @SHYFTAnalytics or LinkedIn.
About Medidata
Medidata is leading the digital transformation of life sciences
with the world's most-used platform for clinical development,
commercial and real-world data. Powered by artificial intelligence
and delivered by #1 ranked industry experts, the Intelligent
Platform for Life Sciences helps pharmaceutical, biotech, medical
device companies and academic researchers accelerate value,
minimize risk and optimize outcomes. Medidata serves more than
1,000 customers and partners worldwide and empowers more than
100,000 certified users every day to create hope for millions of
patients. Discover the future of life sciences: www.mdsol.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180724005288/en/
Medidata SolutionsInvestors:Betsy Frank, +1
917-522-4620bfrank@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Sep 2023 to Sep 2024